Skip to content
Jevtana kit, Jevtana(cabazitaxel)
Jevtana (cabazitaxel) is a small molecule pharmaceutical. Cabazitaxel was first approved as Jevtana kit on 2010-06-17. It is used to treat prostatic neoplasms in the USA. It has been approved in Europe to treat castration-resistant prostatic neoplasms and prostatic neoplasms. The pharmaceutical is active against tubulin beta chain.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
Trade Name
FDA
EMA
Jevtana (generic drugs available since 2022-06-23)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cabazitaxel
Tradename
Company
Number
Date
Products
CABAZITAXELACCORD HLTHCAREN-207949 RX2021-12-29
1 products, RLD, RS
CABAZITAXELSandozN-208715 RX2023-01-05
2 products, RLD, RS
JEVTANA KITSanofiN-201023 RX2010-06-17
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
jevtanaNew Drug Application2021-02-25
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
prostatic neoplasms—D011471C61
Agency Specific
FDA
EMA
Expiration
Code
CABAZITAXEL, JEVTANA KIT, SANOFI AVENTIS US
2023-12-18M-128
Patent Expiration
Patent
Expires
Flag
FDA Information
Cabazitaxel, Jevtana Kit, Sanofi Aventis Us
89275922030-10-27U-3200
105831102030-10-27U-2753
107167772030-10-27U-2856
72419072025-12-10DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01C: Plant alkaloids and other natural products, antineoplastic drugs
— L01CD: Taxanes, antineoplastic
— L01CD04: Cabazitaxel
HCPCS
Code
Description
J9043
Injection, cabazitaxel, 1 mg
Clinical
Clinical Trials
106 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471C61113294152
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Castration-resistant prostatic neoplasmsD0641295123—118
NeoplasmsD009369C80731——9
AdenocarcinomaD000230151——6
Neoplasm metastasisD009362EFO_0009708—11——1
Transitional cell carcinomaD002295—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5015———6
Brain neoplasmsD001932EFO_0003833C7113———3
Stomach neoplasmsD013274EFO_0003897C1613———3
Non-small-cell lung carcinomaD002289—3———3
Neuroendocrine carcinomaD018278—2———2
Small cell carcinomaD01828812———2
Circulating neoplastic cellsD009360—2———2
Ovarian neoplasmsD010051EFO_0003893C56—2———2
Urologic neoplasmsD014571C64-C68—2———2
Squamous cell carcinoma of head and neckD00007719511———2
Show 12 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelodysplastic syndromesD009190D461————1
Myeloid leukemia acuteD015470C92.01————1
Hematologic neoplasmsD0193371————1
Pancreatic neoplasmsD010190EFO_0003860C251————1
Non-hodgkin lymphomaD008228C85.91————1
Primary myelofibrosisD055728D47.41————1
Multiple myelomaD009101C90.01————1
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.01————1
B-cell chronic lymphocytic leukemiaD015451C91.11————1
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_00003401————1
Show 6 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCABAZITAXEL
INNcabazitaxel
Description
Cabazitaxel is a tetracyclic diterpenoid that is 10-deacetylbaccatin III having O-methyl groups attached at positions 7 and 10 as well as an O-(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl group attached at position 13. Acts as a microtubule inhibitor, binds tubulin and promotes microtubule assembly and simultaneously inhibits disassembly. It has a role as an antineoplastic agent and a microtubule-stabilising agent. It is functionally related to a 10-deacetylbaccatin III.
Classification
Small molecule
Drug classantineoplastics, taxane derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C
Identifiers
PDB—
CAS-ID183133-96-2
RxCUI996051
ChEMBL IDCHEMBL1201748
ChEBI ID63584
PubChem CID9854073
DrugBankDB06772
UNII ID51F690397J (ChemIDplus, GSRS)
Target
Agency Approved
TUBB
TUBB
Organism
Homo sapiens
Gene name
TUBB
Gene synonyms
TUBB5
NCBI Gene ID
203068
Protein name
tubulin beta chain
Protein synonyms
beta Ib tubulin, epididymis secretory sperm binding protein, tubulin beta-1 chain, Tubulin beta-5 chain, tubulin, beta polypeptide
Uniprot ID
P07437
Mouse ortholog
Tubb5 (22154)
tubulin beta-5 chain (Q3UF52)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Jevtana - Sanofi
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,292 documents
View more details
Safety
Black-box Warning
Black-box warning for: Jevtana
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,966 adverse events reported
View more details